KNSA
Kiniksa Pharmaceuticals International, Plc Health Care Pharmaceutical Preparations Russell 3000
$92.24Close
$37.01 – $97.5652-week range
Jan 26, 2027Next report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
- Accumulation up-day volume 1.5× down-day volume over 50 sessions
- Earnings growing EPS +142% year on year, faster than the quarter before (+109 pts)
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
5%
1wk
up 20.2%
price change
1mo
up 23.6%
price change
12-month return
up 147%
market up 11% ·
its own up 136%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
up 60%
year on year
EPS growth
up 142%
latest quarter · +109 pts
Sales growth
up 58%
latest quarter · +3 pts
ROE
up 12%
return on equity
Free cash margin
up 20%
$136.4M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-2.1×
net cash
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Gross margin 85.6% → 88.5%
Trade setup
ATR%
5.1%
$4.71 a day · 2×ATR $82.82
RS
97 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.0×
vs 50-day average
Up/down volume
1.54
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 27, 2026
Results reaction
Oct 27, 2026+30% vs market2 sessions after results
Financials
- Gross 89%
- Net 9%
- Free cash 20%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M |
| Gross margin | — | 76% | 90% | 88% | 86% | 89% |
| Operating income | -$157.4M | -$156.6M | $9.8M | -$25.2M | -$45.6M | $77.2M |
| Net income | -$161.4M | -$157.9M | $183.4M | $14.1M | -$43.2M | $59.0M |
| Net margin | — | -410% | 83% | 5% | -10% | 9% |
| Earnings per share | -$2.61 | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Free cash flow | -$136.8M | -$126.7M | $5.7M | $13.2M | $25.4M | $136.4M |
| Free cash margin | — | -329% | 3% | 5% | 6% | 20% |
| Cash | $114.0M | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M |
| Shareholders' equity | $311.9M | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 27, 2026 | Quarterly ↗ | Sep 30, 2026 | 27d |
| Jul 28, 2026 | Quarterly ↗ | Jun 30, 2026 | 28d |
| Apr 28, 2026 | Quarterly ↗ | Mar 31, 2026 | 28d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Jul 29, 2025 | Quarterly ↗ | Jun 30, 2025 | 29d |
| Apr 29, 2025 | Quarterly ↗ | Mar 31, 2025 | 29d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Oct 29, 2024 | Quarterly ↗ | Sep 30, 2024 | 29d |
| Jul 25, 2024 | Quarterly ↗ | Jun 30, 2024 | 25d |
| Apr 25, 2024 | Quarterly ↗ | Mar 31, 2024 | 25d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Oct 22, 2026 | Director or officer change ↗ |
| Jul 28, 2026 | Results ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 26, 2026 | Material agreement ↗ |
| May 1, 2026 | Director or officer change ↗ |
| Apr 28, 2026 | Results ↗ |
| Feb 24, 2026 | Results ↗ |
| Jan 14, 2026 | Director or officer change ↗ |
| Jan 12, 2026 | Results ↗ |
| Oct 28, 2025 | Results ↗ |
| Sep 3, 2025 | Regulation FD ↗ |